Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
All >

Deals > Western Europe

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Western Europe or involving organisations from these countries.

Total search results: 7020 | Ordered by Date (descending)
1 2 3 ... 69 70 71  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Arxspan–Bruker Corp: investment, 201903 acquisition €na of Arxspan LLC by Bruker Corp 2019-03-14
Uniqure–Barclays: investor conference, 201903 supply service Uniqure presents at Barclays Global Healthcare Conference in Miami 2019-03-13
Uniqure–Life Sciences Partners: investor conference, 201903 supply service Uniqure presents at BioCapital Europe 2019-03-13
Snipr Biome–Life Sciences Partners: investment, 201903 financing round Series A totalling $50m incl co-lead investor LSP 2019-03-11
Snipr Biome–Wellington Partners: investment, 201903 financing round Series A totalling $50m incl co-investor Wellington Partners 2019-03-11
Qiagen–Tecan: lab automation, 201903– collab direct supply of Tecan Fluent workstation for sample to labs using QuantiFeron-TB Gold Plus test 2019-03-08
Gilde Investment–SEVERAL: investment, 201903 final close €200m Gilde Healthcare Service III fund incl PGGM/PF Zorg en Welzijn + Rabo Corp Investments 2019-03-07
BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m 2019-03-05
Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB 2019-03-05
abcr GmbH–Enzymicals: enzymes, 201903– collab distribution expansion ww sale of all catalogue products of Enzymcials by acbr 2019-03-04
Nightstar Therapeutics–Biogen: investment, 201903– acquisition $877m in cash at $25.5/share ANNOUNCED 2019-03-04
Anaeropharma Science–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
CEPI–CureVac: mRNA vaccine production technology, 201903–202202 collab up to $34m developm of mobile mRNA printing facility 2019-03-01
Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners 2019-03-01
Uniqure–Cowen: investor conference, 201903 supply service Uniqure presents at Cowen & Co Annual Health Care Conference 2019 2019-03-01
Uniqure–Silicon Valley Bank: investor conference, 201903 supply service Uniqure presents at SVB Leerink Partners Global Healthcare Conference in NYC 2019-03-01
iOnctura–Optimum Strategic Communications: public relations, 201902 service existent by Optimum 2019-02-28
Sarepta Therapeutics–Centogene: molecular diagnostics, 201902–202002 collab service identifying DMD patients in MENA region by Centogene 2019-02-28
CureVac–Silicon Valley Bank: investor conference, 201902 supply service CureVac presents at SVB Leerink Partners Global Healthcare Conference in NYC 2019-02-27
Genfit–SEVERAL: investment, 201902– private placement of ordinary shares in Europe + outside North America 2019-02-27
Genfit–SEVERAL: investment, 201902– US IPO of ADSs FILED 2019-02-27
Versum Materials–Merck (DE): investment, 201902– unsolicited all-cash offer at $48/share by Merck 2019-02-27
Anaveon–Novartis: investment, 201902 financing round Series A totalling CHF35m incl co-investor Novartis Venture Fund 2019-02-26
Anaveon–SEVERAL: investment, 201902 financing round Series A CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Anaveon–Wellcome Trust: investment, 201902 financing round Series A totalling CHF35m incl CHF28m from lead investor Syncona Ltd 2019-02-26
Roche–Citigroup: financial services, 201902 supply Citi financial advisor to Roche with regard to acquisition of Spark by Roche 2019-02-25
Roche–Davis Polk & Wardwell: legal services, 201902 supply service legal advisor to Roche w regard acquisition of Spark Therapeutics 2019-02-25
Spark Therapeutics–Roche: investment, 201902– acquisition $4.3b cash tender offer for all shares at $114.5/share ANNOUNCED 2019-02-25
Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures 2019-02-21
Aidence–ABP (NL): investment, 201902 financing round Series A totalling €10m incl lead investor Inkef Capital 2019-02-20
Aidence–Rabo Ventures: investment, 201902 financing round Series A totalling €10m incl co-investor Rabo Ventures 2019-02-20
Aidence–SEVERAL: investment, 201902 financing round Series A €10m led by Inkef Capital + co-investor Rabo Ventures et al 2019-02-20
Alchemist Accelerator–BASF: investment, 201902 BASF Venture Capital invests $2m + becomes Limited Partner 2019-02-20
BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund 2019-02-20
BPCE–Yucatan: public relations, 201902 service existent media relations for Seventure Parnters in France by Agence Yucatan 2019-02-20
Calypso Biotech–ABP (NL): investment, 201902 financing round Series A totallling €20m incl co-lead investor Inkef Capital 2019-02-20
Calypso Biotech–Gilde Investment: investment, 201902 financing round Series A totallling €20m incl co-lead investor Gilde Healthcare 2019-02-20
Calypso Biotech–JnJ: investment, 201902 financing round Series A totallling €20m incl co-investor JnJ Innovation JJDC 2019-02-20
Calypso Biotech–Merck (DE): investment, 201902 financing round Series A totallling €20m incl co- + founding investor M Ventures 2019-02-20
Calypso Biotech–SEVERAL: investment, 201902 financing round Series A €20m co-led by Gilde Healthcare + Inkef Capital 2019-02-20
Evotec–Helmholtz: antibiotics, 201902– collab development with initial focus on cystobactamids with Helmholtz HZI Braunschweig 2019-02-20
CRISPR Therapeutics–StrideBio: AAV vectors, 201902– collab expansion €na of developm + license option usingStrideBio’s vectors for CRISPR therapies 2019-02-19
Gain Therapeutics–Fondazione Centenario BancaStato: investment, 201902 financing round Series A totalling €2.5m incl €400k from TiVenture SA 2019-02-19
Gain Therapeutics–Helsinn: investment, 201902 financing round Series A totalling €2.5m incl €1m from new investor Helsinn Investment Fund SA 2019-02-19
Gain Therapeutics–SEVERAL: investment, 201902 financing round Series A €2.5m from VitaTech + Helsinn Investment Fund + TiVenture 2019-02-19
Gain Therapeutics–VitaTech: investment, 201902 financing round Series A totalling €2.5m incl €1.1m from new investor VitaTech SA 2019-02-19
Qiagen–Curetis: bioinformatics, 201902– license excl to use ARESdb for general bioinformatics research offerings + services for AMR research 2019-02-18
S-Biomedic–DSM: investment, 201902 financing round Series A 2nd closing totalling €2m incl new investor DSM Venturing 2019-02-18
S-Biomedic–SEVERAL: investment, 201902 financing round Series A 2nd closing €2m from new investor DSM Venturing + existing investor investiere.ch 2019-02-18
S-Biomedic–Verve Capital Partners: investment, 201902 financing round Series A 2nd closing totalling €2m incl existing investor investiere.ch 2019-02-18
Arvelle Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling $180m incl investor Andera Partners 2019-02-14
Arvelle Therapeutics–BRV Capital: investment, 201902 financing round Series A totalling $180m incl investor BRV Capital Management 2019-02-14
Arvelle Therapeutics–H.I.G. Capital: investment, 201902 financing round Series A totalling $180m incl investor H.I.G. BioHealth Partners 2019-02-14
Arvelle Therapeutics–Life Sciences Partners: investment, 201902 financing round Series A totalling $180m incl lead investor LSP 2019-02-14
Arvelle Therapeutics–NovaQuest Capital: investment, 201902 financing round Series A totalling $180m incl investor NovaQuest Capital Management 2019-02-14
Arvelle Therapeutics–Sam Brown: public relations, 201902 service existent by Sam Brown Inc 2019-02-14
Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate 2019-02-14
Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals 2019-02-14
Novartis–AbCellera: therapeutic antibodies, 201902– collab discovery use of AbCellera technology + screening for up to ten targets 2019-02-14
Plasmion–Bavaria (govt): investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–High-Tech Gründerfonds: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–PERSON: investment, 201902 financing round totalling almost €1m from HTGF + BayBG + business angel 2019-02-14
Plasmion–SEVERAL: investment, 201902 financing round almost €1m from HTGF + BayBG + business angel 2019-02-14
CiToxLab–Charles River: investment, 201902– acquisition $448m in cash BINDING OFFER SIGNED 2019-02-13
Grey Wolf Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan 2019-02-11
Symrise–SEVERAL: investment, 201902 capital increase €400m with 5.614m new shares at €71.25/share to fund acquisition of ADF/IDF 2019-02-08
Galapagos–Evotec: antifibrotic, 201902– collab + ww commercial rights for Galapagos to small-molecule programme for fibrotic diseases 2019-02-07
Invisible Sentinel–Mérieux: investment, 201902 acquisition $75m in cash by bioMérieux 2019-02-07
Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research 2019-02-06
Bruker Corp–Genedata: drug screening software, 201902 collab product integration Bruker new Ready-to-Run partner 2019-02-05
Lilly–ProteoNic: rec protein production technology, 201902– license non-excl €na to use 2G UNic technology to boost rec protein production 2019-02-05
Argen-X–Halozyme: drug delivery technology, 201901– collab + license agreem ww for Enhanze technology $30m upfront + milestones + royalties 2019-02-04
Macherey-Nagel–Andrew Alliance: automated liquid handling technology, 201902–collab co-marketing NucleoBond kits with OneLab s/w + Andrew+ robot 2019-02-04
United Kingdom (govt)–Qiagen: bioinformatics, 201902– supply Genomics England selects QCI for genome sequencing project of NHS 2019-02-04
Axial Biotherapeutics–BPCE: investment, 201902 financing round Series B totalling $25m incl new investor Seventure Partners 2019-02-01
ADF/IDF–Symrise: investment, 201901– acquisition $900m by Symrise ANNOUNCED 2019-01-31
Apceth–Hitachi: investment, 201901–201904 acquisition €75.5m 100% of Apceth Biopharma GmbH from Apceth GmbH by Hitachi Chemical 2019-01-31
Bayer–Univ Kyoto: drug discovery, 201901– collab €na research alliance for drug target discovery for pulmonary diseases incl IPF 2019-01-31
Medizinsches Labor Hannover–Labor Limbach: investment, 201901 acquisition 100% of MLH by Limbach Gruppe SE PENDING 2019-01-26
Biocartis–SEVERAL: investment, 201901 private placement €55.5m of 5m new shares at €11.1/share 2019-01-23
MAB Discovery–BioNTech: investment, 201901–201903 acquisition €na of Antibody Generation Unit of MAB Discovery by BioNTech 2019-01-23
CRISPR Therapeutics–Minapharm: gene transfer technology, 201901– collab + license €na with ProBioGen to develop in vivo delivery technology for CRISPR 2019-01-22
Scailyte–SEVERAL: investment, 201901 seed financing round CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Scailyte–Swisscom: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Scailyte–Zürcher Kantonalbank: investment, 201901 seed financing round totalling CHF2.75m incl new investors Swisscom Ventures + Zürcher Kantonalbank 2019-01-22
Link Health–Marinomed: drug delivery technology, 201901– collab registration + distribution of Marinosolv products in China by Link Health 2019-01-21
ImaBiotech–Metabrain Research: preclinical research services, 201901– collab strategic partnership ADMET services in preclin metabolic disease models 2019-01-17
ImaBiotech–OCR (FR): preclinical research services, 201901– collab strategic partnership oncology research in pet tumors using bioanalytical imaging 2019-01-17
Miltenyi Biotec–Univ Duisburg-Essen: imaging technology, 201901 acquisition process for opitcal clearing of biological samples for miccrosopy 2019-01-17
Mologen–SEVERAL: credit, 201901–202701 convertible bonds €2.7m at 6% incl existing shareholders 2019-01-17
Mecuris–Bavaria (govt): investment, 201901 financing round Series A totalling €3.6m incl existing investor Bayern Kapital GmbH 2019-01-16
Mecuris–High-Tech Gründerfonds: investment, 201901 financing round Series A totalling €3.6m incl existing investor HTGF 2019-01-16
Mecuris–Mulcan: investment, 201901 financing round Series A totalling €3.6m incl new investor MII Mulcan International Investments GmbH 2019-01-16
Mecuris–OTHER: investment, 201901 financing round Series A totalling €3.6m incl new investor one of largest German hospital chains 2019-01-16
Mecuris–SEVERAL: investment, 201901 financing round Series A €3.6m incl Bayern Kapital + HTGF + Vesalius Biocapital + Mulcan et al. 2019-01-16
Mecuris–Vesalius Biocapital: investment, 201901 financing round Series A totalling €3.6m incl new investor Vesalius Biocapital III SICAR 2019-01-16
Nanobiotix–RooneyPartners: public relations, 201901 service existent US media relations by RooneyPartners 2019-01-16
Nanobiotix–SEVERAL: investment, 201901– filing of Form F-1 for registered public offering of shares + ADSs in US conditions to be determined later 2019-01-16
1 2 3 ... 69 70 71  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top